Trial Profile

A Multicenter Randomized, Open-label Study to Compare the Efficacy of Subcutaneous Infliximab Monotherapy with Subcutaneous Infliximab and Concomitant Immunosuppression in the Treatment of Moderate to Severe Crohn's Disease

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 12 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azathioprine (Primary) ; Infliximab (Primary) ; Mercaptopurine (Primary) ; Methotrexate (Primary) ; Tioguanine (Primary) ; Folic acid
Indications Crohn's disease
Focus Therapeutic Use
Acronyms DIRECTCD

10 Dec 2024 Planned End Date changed from 1 Jul 2024 to 1 Dec 2025.
10 Dec 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jun 2025.
03 Oct 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com